Quidel is a pharmaceutical company focusing on point-of-care diagnostic solutions, infectious diseases, and reproductive and women's health. Established in 1979 and headquartered in San Diego, California, the company offers a range of products under various brand names, including QuickVue, QuickVue+, QuickVue Advance, Metra, Quidel, and MicroVue. Their diagnostic tests cater to infectious diseases such as Influenza, Group A Strep, and Respiratory Syncytial Virus, as well as reproductive and women's health issues like pregnancy, Chlamydia, Bacterial Vaginosis, and Bone Health.
Led by CEO Douglas C. Bryant, Quidel employs around 1,500 workers and generates annual revenue of approximately $1.7 billion. The company has a diverse workforce with 42% female employees and 50.3% ethnic minorities. Quidel sells its products to professionals in healthcare settings such as physician offices, hospitals, clinical laboratories, and wellness screening centers. They have a strong presence in the United States and in international markets like Japan, Europe, and the Middle East.
